MannKind's CEO Discusses Q4 2011 Results - Earnings Call Transcript

MannKind (MNKD)

Q4 2011 Earnings Call

February 22, 2012 5:00 pm ET


Matthew J. Pfeffer - Chief Financial Officer, Principal Accounting Officer and Corporate Vice President

Hakan S. Edstrom - President, Chief Operating Officer and Director

Alfred E. Mann - Founder, Chairman and Chief Executive Officer


Thomas J. Russo - Robert W. Baird & Co. Incorporated, Research Division

Steve Byrne - BofA Merrill Lynch, Research Division

Keith A. Markey - Griffin Securities, Inc., Research Division



Ladies and gentlemen, thank you for standing by. Welcome to the MannKind Corporation Fourth Quarter and Year-end 2011 Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, February 22, 2012. Joining us today for MannKind are Chairman and CEO, Alfred Mann; President and COO, Hakan Edstrom; and Chief Financial Officer, Matthew Pfeffer. I would now like to turn the call over to Matthew Pfeffer, Chief Financial Officer of MannKind Corporation. Please go ahead.

Matthew J. Pfeffer

Good afternoon, and thank you for participating in today's call. I'll summarize our financial results for 2011, as reported earlier today, and also our recent financing activities. Hakan will then discuss our current operations and Al will conclude with an overview before we open the call to your questions.

Before I proceed further, please note that comments made during this call will include forward-looking statements within the meaning of Federal Securities Laws. It is possible that the actual results could differ from these stated expectations. For factors which could cause actual results to differ from expectations, please refer to the reports filed by the company with the Securities and Exchange Commission under the Securities and Exchange Act of 1934.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind